Glycosaminoglycan mimetic improves enrichment and cell functions of human endothelial progenitor cell colonies

• Published in: Stem cell research 2014-05, Vol.12 (3), p.703-715
• Main Authors: Chevalier, Fabien, Lavergne, Mélanie, Negroni, Elisa, Ferratge, Ségolène, Carpentier, Gilles, Gilbert-Sirieix, Marie, Siñeriz, Fernando, Uzan, Georges, Albanese, Patricia
• Format: Article
• Language: English
• Subjects: Cell Adhesion; Cell Movement; Cell Proliferation; Colony-Forming Units Assay; Endothelial Progenitor Cells - cytology; Endothelial Progenitor Cells - metabolism; Female; Fetal Blood - cytology; Glycosaminoglycans - chemistry; Glycosaminoglycans - metabolism; Humans; Infant, Newborn; Life Sciences; Male
• ISSN: 1873-5061; 1876-7753; 1876-7753
• DOI: 10.1016/j.scr.2014.03.001

Human circulating endothelial progenitor cells isolated from peripheral blood generate in culture cells with features of endothelial cells named late-outgrowth endothelial colony-forming cells (ECFC). In adult blood, ECFC display a constant quantitative and qualitative decline during life span. Even after expansion, it is difficult to reach the cell dose required for cell therapy of vascular diseases, thus limiting the clinical use of these cells. Glycosaminoglycans (GAG) are components from the extracellular matrix (ECM) that are able to interact and potentiate heparin binding growth factor (HBGF) activities. According to these relevant biological properties of GAG, we designed a GAG mimetic having the capacity to increase the yield of ECFC production from blood and to improve functionality of their endothelial outgrowth. We demonstrate that the addition of [OTR4131] mimetic during the isolation process of ECFC from Cord Blood induces a 3 fold increase in the number of colonies. Moreover, addition of [OTR4131] to cell culture media improves adhesion, proliferation, migration and self-renewal of ECFC. We provide evidence showing that GAG mimetics may have great interest for cell therapy applied to vascular regeneration therapy and represent an alternative to exogenous growth factor treatments to optimize potential therapeutic properties of ECFC. [Display omitted] •We designed a GAG mimetic [OTR4131] which increases the yield of ECFC from blood.•[OTR4131] potentiates heparin binding growth factor effects on ECFC proliferation.•[OTR4131] doubles the capacity of a single ECFC to give rise to a clonal progeny.•[OTR4131] improves adhesion and migration of human ECFC.